Veracyte, Inc. (VCYT)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$47.93+4.11%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Veracyte, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.4%

+10% or more+5%0%−5%−10% or less

1.95 → 1.94 EPS · FY ending Dec 31, 2027 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	157.29M
EPS	—	0.446
Annual ending 2026-12-31
Revenue	—	593.83M
EPS	—	1.91
Annual ending 2027-12-31
Revenue	—	660.04M
EPS	—	1.944

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash from operations grows above $35M	Cash from operations jumped from $5.4M to $35.2M, supporting growth and investments.	Intact	Cash from operations falls below $30M over next year	Cash from operations: $45.826M FY2026-Q2; GAAP. Published target: Cash from operations >= $35M. Target period is not explicitly aligned with this observation. Source published Jul 31, 202645,826,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 quarters including 2026-Q1 and 2026-Q2. Cash from operations grew from $38.97 million in the first half of 2025 to $81.0 million in the first half of 2026. This doubling of cash flow indicates management is delivering on increasing cash from operations. Delivery assessment Oct 24, 2026
Operating income improves to sustain growth	Profit rises with better cost control, shown by operating income up from $2.9M to $22.6M.	Intact	Operating income falls below prior year levels or turns negative	Operating income: $22.98M FY2026-Q2; GAAP. Published target: Operating income remains positive and growing. Target period is not explicitly aligned with this observation. Source published Jul 31, 202622,980,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 2ec3c0f9-bd24-40ba-ab82-5b6a8dbfd581. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue grows to about $575M in FY26	Veracyte grows revenue about 13% yearly, driven by new tests.	Intact	Revenue falls below $570M in FY26	Revenue: $150.321M FY2026-Q2; GAAP. Published target: ~$575M. Target period is not explicitly aligned with this observation. Source published Jul 31, 2026150,321,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 2ec3c0f9-bd24-40ba-ab82-5b6a8dbfd581. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 quarters including 2026-Q1 and 2026-Q2. Revenue grew from $139.1 million in 2026-Q1 to $150.3 million in 2026-Q2, representing 15% year-over-year growth in Q2 and 21% in Q1. This trajectory matches management's repeated emphasis on strong double-digit revenue growth and new product launches, indicating delivery on this priority. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$1.94

$1.88 → $1.94 · observed estimates

FY2027 revenue$0.66B

$0.66B → $0.66B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$1.88	$655,981,228	7 / 9
2026-07-25	$1.89	$654,944,910	11 / 12
2026-07-26	$1.89	$654,944,910	11 / 12
2026-07-27	$1.89	$654,944,910	11 / 12
2026-07-28	$1.89	$654,944,910	11 / 12
2026-07-29	$1.88	$655,981,228	7 / 9
2026-07-30	$1.89	$654,944,910	11 / 12
2026-07-31	$1.89	$654,944,910	11 / 12
2026-08-01	$1.88	$655,981,228	7 / 9
2026-08-02	$1.93	$656,785,450	10 / 11
2026-08-03	$1.93	$656,785,450	10 / 11
2026-08-04	$1.93	$656,785,450	10 / 11
2026-08-05	$1.85	$657,927,587	5 / 8
2026-08-06	$1.95	$659,215,760	11 / 12
2026-08-08	$1.85	$657,927,587	5 / 8
2026-08-09	$1.95	$659,215,760	11 / 12
2026-08-10	$1.95	$659,215,760	11 / 12
2026-08-12	$1.85	$657,927,587	5 / 8
2026-08-13	$1.95	$659,215,760	11 / 12
2026-08-14	$1.85	$657,927,587	5 / 8
2026-08-15	$1.85	$657,927,587	5 / 8
2026-08-16	$1.85	$657,927,587	6 / 8
2026-08-17	$1.85	$657,927,587	6 / 8
2026-08-18	$1.85	$657,927,587	6 / 8
2026-08-19	$1.85	$657,927,587	6 / 8
2026-08-20	$1.95	$659,223,362	7 / 9
2026-08-21	$1.95	$659,223,362	7 / 9
2026-08-22	$1.95	$659,223,362	7 / 9
2026-08-23	$1.95	$659,223,362	7 / 9
2026-08-24	$1.95	$659,223,362	7 / 9
2026-08-25	$1.95	$659,223,362	7 / 9
2026-08-26	$1.95	$659,223,362	7 / 9
2026-08-27	$1.95	$659,223,362	7 / 9
2026-08-28	$1.95	$659,223,362	7 / 9
2026-08-29	$1.95	$659,223,362	7 / 9
2026-08-30	$1.95	$659,223,362	7 / 9
2026-08-31	$1.95	$659,223,362	7 / 9
2026-09-01	$1.95	$659,223,362	7 / 9
2026-09-02	$1.95	$659,223,362	7 / 9
2026-09-03	$1.95	$659,223,362	7 / 9
2026-09-04	$1.95	$659,223,362	7 / 9
2026-09-05	$1.95	$659,223,362	7 / 9
2026-09-06	$1.95	$659,223,362	7 / 9
2026-09-07	$1.95	$659,223,362	7 / 9
2026-09-08	$1.95	$659,223,362	7 / 9
2026-09-09	$1.95	$659,223,362	7 / 9
2026-09-10	$1.95	$659,219,279	7 / 9
2026-09-11	$1.96	$660,491,037	7 / 9
2026-09-12	$1.96	$660,491,037	7 / 9
2026-09-13	$1.96	$660,491,037	7 / 9
2026-09-14	$1.96	$660,491,037	7 / 9
2026-09-15	$1.96	$660,491,037	7 / 9
2026-09-16	$1.95	$660,492,406	7 / 9
2026-09-17	$1.95	$660,492,406	7 / 9
2026-09-18	$1.95	$660,492,406	7 / 9
2026-09-19	$1.95	$660,492,406	7 / 9
2026-09-20	$1.95	$660,492,406	7 / 9
2026-09-21	$1.95	$660,492,406	7 / 9
2026-09-22	$1.95	$660,492,406	7 / 9
2026-09-23	$1.95	$660,492,406	7 / 9
2026-09-24	$1.95	$660,488,637	7 / 9
2026-09-25	$1.95	$660,488,637	7 / 9
2026-09-26	$1.95	$660,488,637	7 / 9
2026-09-27	$1.95	$660,488,637	7 / 9
2026-09-28	$1.95	$660,488,637	7 / 9
2026-09-29	$1.95	$660,488,637	7 / 9
2026-09-30	$1.95	$660,488,637	7 / 9
2026-10-01	$1.95	$660,488,637	7 / 9
2026-10-02	$1.95	$660,488,637	7 / 9
2026-10-03	$1.95	$660,242,483	7 / 9
2026-10-04	$1.95	$660,242,483	7 / 9
2026-10-05	$1.95	$660,242,483	7 / 9
2026-10-06	$1.95	$660,242,483	7 / 9
2026-10-07	$1.95	$660,242,483	7 / 9
2026-10-08	$1.95	$660,242,483	7 / 9
2026-10-09	$1.95	$658,622,561	7 / 9
2026-10-10	$1.95	$658,622,561	7 / 9
2026-10-11	$1.95	$658,622,561	7 / 9
2026-10-12	$1.95	$658,622,561	7 / 9
2026-10-13	$1.95	$658,622,561	7 / 9
2026-10-14	$1.95	$658,618,937	7 / 9
2026-10-15	$1.95	$658,618,937	7 / 9
2026-10-16	$1.95	$658,618,937	7 / 9
2026-10-17	$1.95	$658,618,937	7 / 9
2026-10-18	$1.95	$658,626,330	7 / 9
2026-10-19	$1.95	$658,626,330	7 / 9
2026-10-20	$1.95	$658,626,330	7 / 9
2026-10-21	$1.95	$658,626,330	7 / 9
2026-10-22	$1.95	$658,626,330	7 / 9
2026-10-23	$1.95	$658,626,330	7 / 9
2026-10-24	$1.94	$660,038,420	7 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	1	1
2026-06-01	9	1	1
2026-07-01	10	1	1
2026-08-01	10	1	1
2026-09-01	11	1	1
2026-10-01	11	1	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash from operations grows above $35MCash from operations: $45.826M
Operating income improves to sustain growthOperating income: $22.98M
Revenue grows to about $575M in FY26Revenue: $150.321M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-39.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Veracyte, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented healthcare business with improving profitability, rather than a turnaround. The multi-year view is intact, with management delivering on its stated priorities, though risk remains elevated.

What's priced into Veracyte, Inc.

Valuation is expensive versus peers, with a 1.1 premium, while the expectations gap is modestly negative. The market appears to recognize the recent operating strength, and the evidence labels current expectations as justified with low fragility.

What the fundamentals likely do

Near term, revenue growth has remained strong, operating income has improved, and cash from operations has increased; management is on track against all three stated priorities. A recent earnings beat and acquisition announcement add context, but the evidence gives limited detail on the acquisition’s likely contribution. Near-term miss risk is rated low, though a past deep miss and possible guidance cuts remain risks.

What Veracyte, Inc. hinges on

Over the next few quarters, the thesis hinges on continued revenue growth and progress in profitability and cash generation. A guidance cut or further weakening in jobs data could pressure the business backdrop, while strong results and guidance from healthcare peers could support sector momentum.